The New Era of mHSPC Treatment: Evaluating Emerging Doublet and Triplet Combinations

Still using androgen deprivation therapy (ADT) alone for patients with metastatic hormone-sensitive prostate cancer (mHSPC)? Learn the latest on optimizing outcomes with combination therapies.

Credit available for this activity expires: 6/25/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/new-era-mhspc-treatment-evaluating-emerging-doublet-and-2026a1000kt7?ecd=bdc_podcast_libsyn_mscpedu